JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. (Nasdaq: TEVA) have signed a collaboration and licensing agreement for the development of two proteins, using Protalix’s plant cell culture platform. The undisclosed proteins, aimed at large-sized markets are not part of Protalix’s current product development pipeline.
